BioSig Announces Closing of Public Offering of Common Stock
March 23 2022 - 8:00AM
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced the completion of its
previously announced underwritten public offering of 2,611,739
shares of its common stock, $0.001 par value per share, at a price
to the public of $1.15 per share. The proceeds to BioSig from this
offering were $3 million. The Company also issued a cash
warrant at $1.40. Fully exercised the Company will receive another
$3m of cash proceeds.
BioSig intends to use the net proceeds from the offering for the
continuation of full commercialization activities related to the
PURE EP™ System.
A shelf registration statement on Form S-3 (Registration No.
333-251859) relating to the public offering of the shares of common
stock described above was previously filed with the Securities and
Exchange Commission (“SEC”) and declared effective on January 12,
2021. A final prospectus supplement and accompanying prospectus
describing the terms of the offering were filed with the SEC on
July 6, 2021, and are available on the SEC’s website at
www.sec.gov. Copies of the final prospectus supplement and
accompanying prospectus relating to the offering may be obtained
from BioSig Technologies, Inc. 55 Greens Farms Road Westport, CT
06880 Attention: Vice President Administration.; email:
lmikolaitis@biosigtech.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or other jurisdiction. Any offer, if at all, will be
made only by means of the prospectus supplement and accompanying
prospectus forming a part of the effective registration
statement.
About BioSig Technologies
BioSig Technologies is a medical technology company
commercializing an innovative biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of
ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
Vice President, Investor Relations
BioSig Technologies, Inc.
55 Greens Farms Road
Westport, CT 06880
203 409-5444, x 133
aballou@biosigtech.com
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024